The entactogens: Ecstasy (MDMA), Eve (MDE) and other ring-substituted methamphetamine derivatives. A novel pharmacological class among the illicit designer drugs?;DIE ENTAKTOGENE 'ECSTASY' (MDMA), 'EVE' (MDE) UND ANDERE RINGSUBSTITUIERTE METHAMPHETAMINDERIVATE. EINE NEUE STOFFKLASSE UNTER DEN ILLEGALEN DESIGNERDROGEN?

Nervenarzt

Volumn 67, Issue 5, 1996, Pages 369-380

  Gouzoulis Mayfrank, E ^a   Hermle, L ^b   Kovar, K A ^c   Sass H ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b Fachkrankenhaus F Neurol P   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

'Ecstasy'; 'Eve'; entactogens; MDE; MDMA

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYETHAMPHETAMINE; 3,4-METHYLENEDIOXYETHAMPHETAMINE; DESIGNER DRUG; DRUG DERIVATIVE;

ANXIETY; DRUG ABUSE; FATALITY; HALLUCINATION; HUMAN; HYPERTHERMIA; LIVER TOXICITY; REVIEW; SIDE EFFECT; STIMULATION; ADDICTION; ANIMAL; PSYCHOLOGICAL ASPECT; RISK FACTOR; WITHDRAWAL SYNDROME;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; DESIGNER DRUGS; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RISK FACTORS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 0029943944     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Adamson S, Metzner R (1988) The nature of the MDMA experience, and its role in healing, psychotherapy, and spiritual practice. Revision 10: 59-72
2. Aghajanian GK (1994) LSD und phenethylamine hallucinogens: common sites of neuronal action: In: Pletscher A, Ladewig D (eds) 50 Years of LSD. Current status and perspectives of hallucinogens. Parthenon, New York London, pp 27-41
3. Allen RP, McCann UD, Ricaurte GA (1993) Persistent effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") on human sleep. Sleep 16: 560-564
4. Anderson GM, Braun G, Braun U, Nichols DE, Shulgin AT (1978) Absolute configuration and psychotomimetic activity. In: Barnett G, Trsic M, Willette R (eds) QUASAR: quantitative structure activity relationships of analgesics, narcotic antagonists, and hallucinogens. NIDA Research Monograph 22. NIDA, Rockville, MD
5. Barret R, Taylor GT (1993) "Ecstasy" ingestion: a case report of severe complications. J R Soc Med 86: 233-234
6. Bastiaans J (1979) Psychotherapy of war victims facilitated by the use of hallucinogenic drugs. In: The Vth World Congress of the International College of Psychosomatic Medicine, Jerusalem
7. Battaglia G, Brooks BP, Kulsakdinum C, DeSouza EB (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymetarnphetamine) at various brain recognition sites. Eur J Pharmacol 149: 159-163
8. Battaglia G, Yeh SY, De Souza EB (1988) MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav 29: 269-274
9. Battaglia G, Zaczek R, De Souza (1990) MDMA effects in brain: Pharmacologic profile and evidence of neurotoxicity from neurochemical and autoradiographic studies. In: Peroutka SJ (ed) Ecstasy: The clinical, pharmacological and neurotoxicological effects of the drug MDMA. Kluwer, Boston, pp 171-199
10. Beck J (1986) MDMA. The popularization and resultant implications of a recently controlled psychoactive substance. Contemp Drug problems 13: 23-63
11. Beck J (1990) The public health implications of MDMA use. In: Peroutka SJ (ed) Ecstasy: The clinical, pharmacological and neurotoxicological effects of the drug MDMA. Kluwer, Boston, pp 77-103
12. Beck J, Morgan PA (1986) Designer drug confusion: a focus on MDMA. J Drug Educ 16: 287-302
13. Benazzi F, Mazzoli M (1991) Psychiatric illness associated with "Ecstasy" (letter). Lancet 338: 1520
14. Benz E (1989) Halluzinogen-unterstützte Psychotherapie. Erhebung bei der Schweizerischen Ärztegesellschaft für Psychoiytische Therapie. Inaugural-Dissertation zur Erlangung der Doktorwürde der Medizinischen Fakultät der Universität Zürich
15. Besser GM, Butler PWP, Laudon J, Rees L (1969) Influence of amphetamines on plasma corticosteroid and growth hormone levels in man. Br J Med 4: 528-530
16. Bravo G, Grob C (1989) Shamans, sacraments, and psychiatrists. J Psychoactive Drugs 21: 123-128
17. Brown GM, Seggie JA, Chambers JW, Ettigi PG (1978) Psychoendocrinology and growth hormone: a review. Psychoneuroendocrinilogy 3: 131-153
18. Creighton FJ, Black DL, Hyde CE (1991) "Ecstasy" psychosis and flashbacks. Br J Psychiatry 159: 713-715
19. Connell PH (1958) Amphetamine psychosis. Maudsley Monographs No. 5. Oxford University Press, London
20. Demisch L, Neubauer M (1979) Stimulation of human prolactin secretion by mescaline. Psychopharmacology 64: 361-363
21. Dowling GP, McDonough ET, Bost RO (1987) "Eve" and "ecstasy": a report of five deaths associated with the use of MDEA and MDMA. JAMA 257: 1615-1617
22. Downing J (1986) The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 18: 335-340
23. Fuller RW (1981) Serotonergic stimulation of pituitary-adrenocortical function in rats. Neuroendocrinology 32: 118-127
24. Gasser P (1995, in Druck) Die psycholytische Psychotherapie in der Schweiz von 1988-1993. Schweiz Arch Neurol Psychiatr
25. Gasser P (1995) Persönliche Mitteilung
26. Gibb JW, Stone D, Johnson M, Hanson GR (1990) Neurochemical effects of MDMA. In: Peroutka SJ (ed) Ecstasy: the clinical, pharmacological and neurotoxkological effects of the drug MDMA. Kluwer, Boston, pp 133-150
27. Glennon RA, Young R, Rosecrans JA, Anderson GM (1982) Discriminative stimulus properties of MDA and related agents. Biol Psychiatry 17: 807-814
28. Goad PT (1985) Report: Acute and subacute oral toxicity study of methylenedioxymethamphetamine in rats. Protocol No. EMD-AT-001. Intox Laboratory, Redfield, AR
29. Gordon CJ, Watkinson WP, O'Callaghan JP, Miller DB (1991) Effects of 3,4-methylenedioxymethamphetamine on automatic thermoregulatory responses of the rat. Pharmacol Biochem Behav 38: 339-344
30. Gouzoulis E, Borchardt D, Kovar K-A, Hermle L (1992) Die "Entaktogene": Eine neue Substanzklasse? Untersuchungen über die psychotropen und neurobiologischen Effekte von 3,4-Methylenedioxyetamphetamin (MDE; "Eve") bei gesunden Probanden. Sucht 38: 114-116
31. Gouzoulis E, Steiger A, Ensslin M, Kovar A, Hermle L (1992) Sleep-EEG effects of 3,4-Methylenedioxyethamphetamine (MDE: "Eve") in healthy volunteers. Biol Psychiatry 32: 1108-1117
32. Gouzoulis E, Bardeleben Uv, Rupp A, Kovar K-A, Hermle L (1993) Neuroendocrine and cardiovascular effects of MDE in healthy volunteers. Neuropsychopharmacology 8: 171-176
33. Gouzoulis E, Borchardt D, Hermle L (1993) A case of toxic psychosis induced by "Eve" (3,4-Methylenedioxyethylamphetamine). Arch Gen Psychiatry 50: 75
34. Gouzoulis-Mayfrank E, Hermle L (1994) Die Gefahren von "Ecstasy" (Leserbrief). Nervenarzt 65: 648-649
35. Greer GR, Tolbert R (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 18: 319-327
36. Greer GR, Tolbert R (1990) The therapeutic use of MDMA. In: Peroutka SJ (ed) Ecstasy: The clinical, pharmacological and neurotoxicological effects of the drug MDMA. Kluwer, Boston, pp 21-35
37. Grinspoon L, Bakalar JB (1986) Can drugs be used to enhance the psychotherapeutic process? Am J Psychotherapy 40: 393-404
38. Grob CS (1994) MDMA research update: the Harbor-UCLA project. Newsletter of the Multidisciplinary Association for psychedelic studies (MAPS), vol IV, Nr 4, pp 2-3
39. Grof S (1983) LSD-Psychotherapie. Klett-Cotta, Stuttgart
40. Gudelsky GA (1981) Tuberoinfundibular dopamine neurons and the regulation of prolactin secretion. Psychoneuroendocrinology 6: 3-16
41. Hardman HF, Haavik CO, Seevers MH (1973) Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicol Appl Pharmacol 25: 299-309
42. Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine. Lancet 340: 384-387
43. Hermle L, Spitzer M, Borchardt D, Kovar K-A, Gouzoulis E (1993) Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents? Neuropsychopharmacology 8: 171-176
44. Johnson M, Hanson GR, Gibb JW (1987) Effects of MDE on central serotonergic and dopaminergic systems of the rat. Biochem Pharmacol 136: 81-88
45. Johnson M, Hoffmann AJ. Nichols DE (1986) Effects of the enantiomers of MDA, MDMA and related analogues on 3H-serotonin and 3H-dopamine release from superfused rat brain slices. Eur J Pharmacol 132: 269-276
46. Karel R (1993) Psychedelic research and the American Psychiatric Association (APA): A panel discussion at APA's 1993 annual meeting. Newsletter of the Multidisciplinary Association for psychedelic studies (MAPS), vol IV, Nr 2, pp 10-12
47. Kovar K-A, Rösch C, Rupp A, Hermle L (1990) Synthetische Suchtstoffe der 2. Generation (sog. designer drugs). Pharm Unserer Zeit 3: 99-107
48. Kovar K-A, Rupp A, Beuerle G, Hermle L, Gouzoulis E (1993) Abgrenzung der Entaktogene von stimulierenden und halluzinogenen Amphetaminen: Ein neues Pharmakophor-Modell für selektive Serotonin-Reuptake-Hemmer. In: Dittrich A, Hofmann A, Leuner HC (Hrsg) Welten des Bewußtseins. Band 1: Ein interdisziplinärer Dialog. Verlag für Wissenschaft und Bildung, Berlin, S 99-107
49. Kovar K-A, Rupp A, Folkerts G (1992) Ein neues Pharmakophor-Modell für selektive 5-HT-Reuptake-Hemmer. Abgrenzung der Entactogene von stimulierenden und halluzinogenen Amfetaminen. Sucht 38: 119-120
50. Kuczenski R, Segal DS (1994) Neurochemistry of amphetamine. In: Cho AK, Segal DS (eds) Amphetamine and its analogs. Pharmacology, toxicology and abuse. Academic Press, San Diego New York Boston, pp 81-114
51. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR (1992) Chronic 3,4-Methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 18: 331-341
52. Leuner HC (1962) Die experimentelle Psychose. Ihre Psychopharmakologie, Phänomenologie und Dynamik in Beziehung zur Person. Springer, Berlin Göttingen Heidelberg
53. Leuner HC (1981) Halluzinogene. Psychische Grenzzustände in Forschung und Psychotherapie. Huber, Bern Stuttgart Wien
54. Leuner HC (1987) Die psycholytische Therapie: Durch Halluzinogene unterstützte tiefenpsychologische Psychotherapie. In: Dittrich A, Scharfetter C (Hrsg) Ethnopsychotherapie. Enke, Stuttgart, S 151-161
55. Lyon RA, Glennon RA, Titeler M (1986) 3,4-Methylenedioxymethamphetamine (MDMA): Stereosclective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology 88: 525-526
56. Matussek N (1988) Catecholamines and mood: Neuroendocrine aspects. In: Ganten D, Pfaff D (eds) Neuroendocrinology of mood. Springer, Berlin Heidelberg New York, pp 141-181
57. McCann UD, Ricaurte GA (1991) Lasting neuropsychiatrie sequelae of (+)Methylenedioxymethamphetamine ("Ecstasy") in recreational users. J Clin Psychopharmacol 11: 302-305
58. McCann UD, Ricaurte GA (1992) MDMA ("Ecstasy") and panic disorder: induction by a single dose. Biol Psychiatry 32: 950-953
59. Mc Elroy JF, Miller JM, Meyer JS (1984) Fenfluramine, p-chloroamphetamine and p-fluoroamphetamine stimulation of pituitary-adrenocortical activity in rat: evidence for differences in site and mechanism of action. J Pharmacol Exp Ther 228: 593-599
60. Mc Guire P, Fahy T (1991) Chronic paranoid psychosis after misuse of MDMA ("ecstasy") (letter). BMJ 302: 697
61. Meltzer HY, Fessier RG, Simonovic M, Fang VS (1978) The effect of mescaline, 3,4-dimethoxylphenethylamine and 2,5-dimethoxy-4-methylamphetamine on rat plasma prolactin: evidence for serotonergic mediation. Life Sci 23: 1185-1192
62. Meltzer HY, Nash JF (1988) Serotonin and mood. Neuroendocrine aspects. In: Ganten D, Pfaff D (eds) Neuroendocrinology of mood. Springer, Berlin Heidelberg New York, pp 183-210
63. Meltzer HY, Simonovic M, Fang VS, Goode DJ (1981) Neuroendocrine effects of psychotomimetic drugs. J McLean Hosp 6: 115-137
64. Nathrath N, Pathologisches Institut, Klinikum rechts der Isar, München (1995) Persönliche Mitteilung
65. Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18: 305-313
66. Nichols DE, Hoffman AJ, Oberlender RA, Jacob P Shulgin AT (1986) Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine. Representatives of a novel therapeutic class. J Med Chemistry 29: 2009-2015
67. Nichols DE, Oberlender R (1990) Structure-activity relationships of MDMA and related compounds: A new class of psychoactive agents? In: Peroutka SJ (ed) Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA. Kluwer, Boston, pp 105-131
68. Pallanti S, Mazzi D (1992) MDMA (Ecstasy) precipitation of panic disorder. Biol Psychiatry 32: 91-95
69. Parkes JD, Debono AG, Jenner P, Walters J (1977) Amphetamines, growth hormone and narcolepsy. Br J Clin Pharmacol 4: 343-349
70. Peroutka SJ (1990) Recreational use of MDMA. In: Peroutka SJ (ed) Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA. Kluwer, Boston, pp 53-62
71. Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1: 273-277
72. Peroutka SJ, Pascoe N, Faull KF (1987) Monoamine metabolites in the cerebrospinal fluid of recreational users of MDMA. Res Commun Substance Abuse 8: 125-138
73. Price LH, Ricaurte GA, Krystal JH, Heninger GR (1989) Neuroendocrine and mood responses to intravenous L-tryptophan in MDMA users. Arch Gen Psychiatry 46: 20-22
74. Ricaurte GA, Bryan G, Strauss L, Seiden L, Schuster C (1985) Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 229: 986-988
75. Ricaurte GA, Finnegan KT, Irwin I, Langsten W (1990) Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: Preliminary observations. Ann NY Acad Sci 600: 699-710
76. Ricaurte GA, Forno LS, Wilson MA, DeLanney LE, Irwin I, Mollivwr ME, Langston JW (1988) MDMA selectively damages central serotonergic neurons in the primate. JAMA 260: 51-55
77. Ricaurte GA, Martello AL, Katz JL, Martello MB (1992) Lasting effects of MDMA on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 261: 616-622
78. Robinson TE, Castaneda E, Whishaw IQ (1993) Effects of cortical serotonin depletion induced by 3,4-Methylenedioxymethamphelamine (MDMA) on behavior, before and after additional cholinergic blockade. Neuropsychopharmacology 8: 77-85
79. Rupp A, Kovar K-A, Beuerle G, Ruf C, Folkers G (1994) A new pharmophoric model for 5-HT reuptake-inhibitors: differentiation of amphetamine analogues. Pharm Acta Helv 68: 235-244
80. Saunders N (1993) MDMA - The view from England. Newsletter of the Multidisciplinary Association for psychedelic studies (MAPS), vol IV, Nr 1, pp 22-24
81. Schmidt CJ (1987) Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs. Eur J Pharmacol 136: 81-88
82. Schmidt CJ, Black CK, Abbate GM, Taylor VL (1990) Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res 529: 85-90
83. Schifano F (1991) Chronic atypical psychosis associated with MDMA ("ecstasy") abuse (letter). Lancet 338: 1335
84. Shulgin AT (1990) History of MDMA. In: Peroutka SJ (ed) Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA. Kluwer, Boston, pp 1-20
85. Steele TD, Nichols DE, Yim GKW (1987) Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoammes into synaptosomes from different regions of rat brain. Biochem Pharmacol 36: 2297-2303
86. Stone DM, Johnson M, Hanson GR, Gibb JW (1987) A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. Eur J Pharmacol 134: 245-248
87. Strassman RJ, Quails CR (1994 a) Dose response study of N,N-dimethyltryptamine in humans. I.Neuroendocrine, autonomie and cardiovascular effects. Arch Gen Psychiatry 51: 85-97
88. Strassman RJ, Quails CR, Uhlenhuth EH, Kellner R (1994b) Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51: 98-108
89. Styk J (1994) Rückblick auf die letzten sieben Jahre der Schweizerischen Ärztegesellschaft für Psycholytische Therapie (SÄPT). In: Dittrich A, Hofmann A, Lcuncr HC (eds) Welten des Bewusstseins, Bd 4: Bedeutung für die Psychotherapie. Verlag für Wissenschaft und Bildung, Berlin, S 149-154
90. Szukai M (1994) MDMA ("Ecstasy") - gefährliche Droge oder Psychotherapeulikum? Nervenarzt 65: 802-805
91. Tehan B, Hardern R, Bodenham A (1993) Hyperthermia associated with 3,4-methylenedioxyethamphetamine ("Eve"). Anaesthesia 48: 507-510
92. Van de Kar LD, Karteszi M, Bethea CL, Ganong WF (1985) Serotonergic stimulation of prolactin and corticosterone secretion is mediated by different pathways from the mediobasal hypothalamus. Neuroendocrinology 41: 380-384
93. Van de Kar LD, Urban JH, Richardson KD, Bethea CL (1985) Pharmacological studies on the serotonergic and nonserotonin-mediated stimulation of prolactin and corticosterone secretion by fenfluramine. Neuroendocrinology 41: 283-288
94. Whitaker-Azmitia PM, Aronson TA (1989) "Ecstasy" (MDMA)-induced panic (letter). Am J Psychiatry 146: 119
95. Widmer PS (1989) Fallbeispiel einer psycholytischen Psychotherapie: Auflösung des psychotischen Kerns bei einer jungen Frau. In: Schlichting H, Leuner HC (Hrsg) Psychoaktive Substanzen und veränderte Bewußtseinszustände in Forschung und Therapie. ECBS, Göttingen, S 163-168
96. Wilson MA, Ricaurte GA, Molliver ME (1989) Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-Methylenedioxymethamphetamine. Neuroscience 28: 121-137
97. Wodarz N, Böning J (1993) Die Gefahren von "Ecstasy". Nervenarzt 64: 478-480
98. Wolfson PE (1986) Meetings at the edge with Adam: A man for all seasons? J Psychoactive drugs 18: 329-333